Bussey HJR (1975) Familial polyposis coli: family studies, histopathology, differential diagnosis and results of treatment. John Hopkins University, Baltimore
Latchford A, Clark S (2023) Is there a role for endoscopic management of the large bowel in Familial adenomatous polyposis?Endoscopy. 55:353–354
Hopper AD (2022) Role of endoscopy in patients with Familial adenomatous polyposis. Frontline Gastroenterol 13(e1):e72–e79
Article PubMed PubMed Central Google Scholar
Cwaliński J, Zasada W, Cholerzyńska H, Andrzejewska W, Michalak H, Banasiewicz T, Paszkowski J (2024) Endoscopic surveillance after (Procto)Colectomy with Gastrointestinal reconstruction in patients with Familial adenomatous polyposis (FAP)—Principles, goals and practical aspects based on 12 years of observation. Life 14(8):1000
Article PubMed PubMed Central Google Scholar
Nugent KP, Spigelman AD, Phillips RK (1993) Life expectancy after colectomy and ileorectal anastomosis for Familial adenomatous polyposis. Dis Colon Rectum 36(11):1059–1062
Article CAS PubMed Google Scholar
Ishikawa H, Yamada M, Sato Y, Tanaka S, Akiko C, Tajika M, Doyama H, Takayama T, Ohda Y, Horimatsu T, Sano Y, Tanakaya K, Ikematsu H, Saida Y, Ishida H, Takeuchi Y, Kashida H, Kiriyama S, Hori S, Lee K, Tashiro J, Kobayashi N, Nakajima T, Suzuki S, Mutoh M (2022) Intensive endoscopic resection for downstaging of polyp burden in patients with Familial adenomatous polyposis (J-FAPP study III): a multicenter prospective interventional study. Endoscopy 55:344–352
PubMed PubMed Central Google Scholar
Falsetti I, Palmini G, Iantomasi T, Brandi ML, Tonelli F (2024) Mechanisms of action of phytoestrogens and their role in Familial adenomatous polyposis. Pharmaceutics 16(5):640
Article CAS PubMed PubMed Central Google Scholar
Aelvoet AS, Pellisé M, Bastiaansen BAJ, van Leerdam ME, Jover R, Balaguer F, Kaminski MF, Karstensen JG, Saurin JC, Hompes R, Bossuyt PMM, Ricciardiello L, Latchford A, Dekker E, European FAP (2023) Personalized endoscopic surveillance and intervention protocols for patients with Familial adenomatous polyposis: the European FAP consortium strategy. Endosc Int Open 11(4):E386–E393
Article PubMed PubMed Central Google Scholar
Yang J, Gurudu SR, Koptiuch C, Agrawal D, Buxbaum JL, Abbas Fehmi SM, Fishman DS, Khashab MA, Jamil LH, Jue TL, Law JK, Lee JK, Naveed M, Qumseya BJ, Sawhney MS, Thosani N, Wani SB, Samadder NJ (2020) American society for Gastrointestinal endoscopy guideline on the role of endoscopy in Familial adenomatous polyposis syndromes. Gastrointest Endosc 91(5):963–982e2
Van Leerdam ME, Roos VH, van Hooft JE et al (2019) Endoscopic management of polyposis syndromes: European society of Gastrointestinal endoscopy (ESGE) guideline. Endoscopy 51:877–895
Anele CC, Martin I, McGinty Duggan PM, Chauhan J, Clark SK, Faiz OD, Latchford AR (2022) Attenuated Familial adenomatous polyposis: A phenotypic diagnosis but obsolete term?? Dis Colon Rectum 65(4):529–535
Church J, Burke C, McGannon E et al (2003) Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for Familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 46:1175–1181
Anele CC, Xiang J, Martin I, Hawkins M, Man R, Clark SK, Faiz OD, Latchford A (2022) Regular endoscopic surveillance and polypectomy is effective in managing rectal adenoma progression following colectomy and ileorectal anastomosis in patients with Familial adenomatous polyposis. Colorectal Dis 24(3):277–283
Bouchiba H, Aelvoet AS, Pellisé M, Bastiaansen BAJ, van Leerdam ME, Langers AMJ, Balaguer F, Miedema TN, Anele CC, Daca-Alvarez M, Bossuyt PMM, Ricciardiello L, Jover R, Hompes R, Karstensen JG, Latchford A, Dekker E, European FAP, Consortium (2024) Risk of cancer and reoperation after ileorectal anastomosis and ileal pouch-anal anastomosis in Familial adenomatous polyposis. Am J Gastroenterol. Dec 31
Ryu HS, Yu CS, Kim YI, Lee JL, Kim CW, Yoon YS, Park IJ, Lim SB, Kim JC (2022) Cumulative incidence and risk factors for pouch adenomas associated with Familial adenomatous polyposis following restorative proctocolectomy. World J Gastroenterol 28(30):4152–4162
Article PubMed PubMed Central Google Scholar
Chika N, Mori Y, Suzuki O, Ishii T, Sugino A, Ishikawa H, Chiyonobu N, Ito T, Tanabe N, Hatano S, Ishiguro T, Matsuyama T, Kumagai Y, Inokuma S, Ishida H (2024) [Development of Cancer of the remnant colorectal segment after Ileal-Pouch anal anastomosis/ileorectal anastomosis in patients with Familial adenomatous polyposis]. Gan Kagaku Ryoho 51(3):336–339
Sriranganathan D, Vinci D, Pellino G, Segal JP (2022) Ileoanal pouch cancers in ulcerative colitis and Familial adenomatous polyposis: A systematic review and meta-analysis. Dig Liver Dis 54(10):1328–1334
Article CAS PubMed Google Scholar
Friederich P, de Jong AE, Mathus- Vliegen LM et al (2008) Risk of developing adenomas and carcinomas in the ileal pouch in patients with Familial adenomatous polyposis. Clin Gastroenterol Hepatol 6:1237–1242
Von Roon AC, Will OCC, Man RF et al (2011) Mucosectomy with handsewn anastomosis reduces the risk of adenoma formation in the anorectal segment after restorative proctocolectomy for Familial adenomatous polyposis. Ann Surg 253:314–317
Boostrom SY, Mathis KL, Pendlimari R et al (2013) Risk of neoplastic change in ileal pouches in Familial adenomatous polyposis. J Gastrointest Surg 17:1804–1808
Gilad O, Tulchinsky H, Kariv R (2023) Surveillance and management of pouch neoplasia in Familial adenomatous polyposis: A systematic review. Diseases of the Colon &Rectum, 67, S82 - S90.
Matsumoto T, Nakamura S, Esaki M et al (2006) Effect of the non-steroidal anti-inflammatory drug Sulindac on colorectal adenomas of uncolectomized Familial adenomatous polyposis. J Gastroenterol Hepatol 21(1 Pt 2):251–257
Article CAS PubMed Google Scholar
Cruz-Correa M, Hylind LM, Romans KE et al (2002) Long-term treatment with Sulindac in Familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122:641–645
Article CAS PubMed Google Scholar
Neuhann TM, Haub K, Steinke-Lange V et al (2022) Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study. Fam Cancer 21:463–472
Article CAS PubMed Google Scholar
Kim KY, Jeon SW, Park JG et al (2014) Regression of colonic adenomas after treatment with Sulindac in Familial adenomatous polyposis: a case with a 2-year follow-up without a prophylactic colectomy. Ann Coloproctol 30:201–204
Article PubMed PubMed Central Google Scholar
Winde G, Schmid KW, Schlegel W et al (1995) Complete reversion and prevention of rectal adenomas in colectomized patients with Familial adenomatous polyposis by rectal low-dose Sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 38:813–830
Article CAS PubMed Google Scholar
Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with Sulindac in Familial adenomatous polyposis. N Engl J Med 328:1313–1316
Article CAS PubMed Google Scholar
Labayle D, Fischer D, Vielh P et al (1991) Sulindac causes regression of rectal polyps in Familial adenomatous polyposis. Gastroenterology 101:635–639
Article CAS PubMed Google Scholar
Nugent KP, Farmer KC, Spigelman AD et al (1993) Randomized controlled trial of the effect of Sulindac on duodenal and rectal polyposis and cell proliferation in patients with Familial adenomatous polyposis. Br J Surg 80:1618–1619
Article CAS PubMed Google Scholar
Giardiello FM, Yang VW, Hylind LM et al (2002) Primary chemoprevention of Familial adenomatous polyposis with Sulindac. N Engl J Med 346:1054–1059
Article CAS PubMed PubMed Central Google Scholar
van Stolk R, Stoner G, Hayton WL et al (2000) Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with Familial adenomatous polyposis. Clin Cancer Res 6:78–89
Samadder NJ, Foster N, McMurray RP et al (2023) Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with Familial adenomatous polyposis. Gut 72:256–263
Article CAS PubMed Google Scholar
Samadder NJ, Neklason DW, Boucher KM et al (2016) Effect of Sulindac and erlotinib vs placebo on duodenal neoplasia in Familial adenomatous polyposis: a randomized clinical trial. JAMA 315:1266–1275
Article CAS PubMed PubMed Central Google Scholar
Samadder NJ, Kuwada SK, Boucher KM et al (2018) Association of Sulindac and erlotinib vs placebo with colorectal neoplasia in Familial adenomatous polyposis: secondary analysis of a randomized clinical trial. JAMA Oncol 4:671–677
Comments (0)